Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses what he thinks are the most important trials and future research directions in ER-positive, HER2-positive, and triple-negative breast cancer. Oral selective estrogen receptor degraders (SERDs) were an exciting topic at SABCS 2021, with promising data being presented. Dr Curigliano also discusses the NATALEE (NCT03701334) and DESTINY-Breast06 (NCT04494425) trials. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.